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High expression of TAZ indicates a poor
prognosis in retinoblastoma
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Abstract
Background: The transcriptional co-activator, TAZ, is an important effector of the Hippo pathway and is critical for
the development of human cancers. However, the expression and prognostic significance of TAZ in retinoblastoma
is currently unclear.
Methods: TAZ expression was examined in 43 retinoblastoma samples by immunohistochemistry. The relationship
between TAZ expression and the clinicopathological features of retinoblastoma was also analyzed. Cox regression
and Kaplan-Meier survival analyses were used to identify the prognostic factors for retinoblastoma patients. Finally,
the effects of TAZ on cell proliferation were explored through lentivirus-mediated downregulation of TAZ in
retinoblastoma cells.
Results: TAZ was highly expressed in retinoblastoma tissues and was associated with regional lymph node classification
(P = 0.013), largest tumor base (P = 0.045), and differentiation (P = 0.019). Moreover, patients with high TAZ expression
had shorter overall survival (OS), progression-free survival (PFS), loco-regional relapse-free survival (LRRFS), and distant
metastasis-free survival (DMFS) time than patients with low TAZ expression (P < 0.05). Multivariate analysis showed that
high TAZ expression was an important prognostic factor for retinoblastoma patients. In addition, downregulation of TAZ
expression significantly suppressed tumor cell proliferation by blocking the transition of the cell cycle from G1 to S phase.
Conclusions: Our findings suggest that the high expression of TAZ plays a significant role in retinoblastoma’s
aggressiveness, and predicts poor prognosis for patients with retinoblastoma.
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Background
Retinoblastoma is an aggressive malignancy of child ret-
ina with 1000 newly diagnosed cases annually in China
[1]. Retinoblastoma affects the eyes of children at a very
young age and accounts for 5 % of blindness in children
[2]. Retinoblastoma often extends along the optic nerve
into the brain and can easily distally metastasize. Al-
though enucleation is necessary in some cases, recent
advances have suggested chemoreduction as the primary
modality of retinoblastoma management, to reduce the
use of enucleation and improve the outcome of patients
[3]. Therefore, exploring the underlying mechanism
responsible for retinoblastoma development may contrib-
ute to finding new therapeutic targets for retinoblastoma
treatment.
Transcriptional co-activator with PDZ-binding motif
(TAZ) is a downstream factor of the Hippo signaling path-
way, which controls cell proliferation and organ size in
mammals [4, 5]. As soon as Hippo signaling is suppressed,
TAZ phosphorylation decreases and it translocates into
the nucleus. Then, TAZ binds to and interacts with several
transcription factors including the TEA domain family
members (TEAD) [6], T-box 5 (TBX5) [7] and paired box-
8 (Pax8) [8], leading to activation of various target genes
that are associated with cell proliferation and tissue
growth. Recently, TAZ has attracted increased interest,
because of its important roles in tumorigenesis. TAZ over-
expression has been found in several human malignant tu-
mors such as oral cancer [9], breast cancer [10], colon
cancer [11] and hepatocellular carcinoma [12]. Moreover,
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TAZ overexpression promoted cell proliferation, migra-
tion and invasion, whereas downregulation of TAZ sup-
pressed cell proliferation, migration and invasion in
hepatocellular carcinoma cells [13] and neuroblastoma
cells [14, 15]. However, the expression and the clinical sig-
nificance of TAZ in retinoblastoma have not been eluci-
dated, yet. In this study, we examined the expression of
TAZ in retinoblastoma tissues, and analyzed its associa-
tions with clinicopathological features and prognosis of
patients with retinoblastoma. We also investigated the role
of TAZ in the proliferation of retinoblastoma cells by
lentivirus-mediated knockdown of TAZ in a retinoblast-
oma cell line.
Methods
Human retinoblastoma cell lines
The human retinoblastoma cell lines, Y79 and WERI-Rb-1,
were used in all experiments. WERI-Rb-1 cell line was
purchased from the Institute of Biochemistry and Cell
Biology of the Chinese Academy of Sciences (Shanghai,
China). Y79 cell line was obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA). All
the cells were maintained in basic RPMI 1640 medium
(Life Technologies, Grand Island, NY, USA) supplemented
with 10 % fetal bovine serum (FBS; Life Technologies) and
1 % penicillin/streptomycin (Life Technologies) at 37 °C in
a humidified atmosphere containing oxygen and 5 % CO2.
Patients and specimens
We obtained human retinoblastoma samples from 50 pa-
tients and 5 normal retinas, and a complete set of follow-
up data. All of the 43 retinoblastoma patients received
enucleation or enucleation + chemotherapy +/− radiation
therapy in the Department of Ophthalmology, Daping
Hospital, Third Military Medical University, between
February 2005 and November 2010. Of the 43 retinoblast-
oma patients there were 18 females and 25 males. The age
of the patients was 0–7 years, with an average age of
2.6 years. All 43 retinoblastoma patients were confirmed
histopathologically and staged based on the American
Joint Commission for Cancer (AJCC) staging system [16].
The last follow-up date was at the end of December 2014.
Other 7 retinoblastoma tissues obtained from patients
received enucleation in the Department of Ophthalmol-
ogy, Daping Hospital, Third Military Medical University,
between November 2014 and March 2015. Five normal
retinas obtained from patients who had died of conditions
other than ophthalmologic diseases in Daping Hospital,
Third Military Medical University. We have written
informed consent from the donor or family members. In
this study, all human participants and human specimens
were approved by the ethics committee of the Third Mili-
tary Medical University, and informed consent was ob-
tained from all patients.
Immunohistochemistry
For standard immunohistochemistry analysis, retino-
blastoma tissue samples were fixed in 4 % formalin and
dehydrated. Then, the tissues were embedded in paraf-
fin. Immunohistochemistry assays were performed on
4-μmthick sections from each paraffin-embedded ret-
inoblastoma specimen. After dewaxing and rehydrating
the sections, antigen retrieval was performed in 10 mM
citrate buffer at 100 °C for 5 min. Next, endogenous
peroxidase activity was blocked using 3 % H2O2 in
methanol for 10 min. Then, the sections were incubated
at 4 °C overnight with mouse polyclonal anti-TAZ
(1:50; BD biosciences, San Jose, CA, USA). After three
washes with phosphate buffered saline (PBS), the sections
were incubated with an anti-mouse secondary antibody for
1 h at room temperature, followed by detection using
streptavidin-horseradish-peroxidase. Finally, the sections
were counterstained with hematoxylin.
Western blot analysis
Retinoblastoma cells were collected by centrifugation, and
then 100 μg of protein extracts isolated with cold RIPA lysis
buffer were separated by 10 % SDS-PAGE. After electro-
phoresis at 100 V for 2 h, proteins were transferred to poly-
vinylidenedifluoride (PVDF) membranes, which were then
blocked with 5 % BSA in Tris-buffered saline containing
0.1 % Tween 20 (TBST) for 2 h at room temperature. Then,
membranes were incubated with a primary antibody against
human TAZ (1:500; BD biosciences), GAPDH (1:1000;
Beyotime), CDK2 (1:500; Santa Cruz, Santa Cruz, CA,
USA), CDK4 (1:500; Santa Cruz), CDK6 (1:500; Santa
Cruz), Cyclin D1 (1:500; Santa Cruz), or Cyclin E (1:500;
Abcam, Cambridge, MA, USA) at 4 °C overnight. After
three 10-min washes with TBST, the membranes were in-
cubated with the corresponding HRP-conjugated secondary
antibody for 2 h at room temperature (1:1000; Santa Cruz).
The targeted bands were visualized with ECL.
RNA isolation and quantitative real-time PCR (qRT-PCR)
Total mRNA from the retinoblastoma and five normal ret-
ina tissues were extracted from snap-frozen tissue, which
was extracted by Trizol reagent (Invitrogen, Carlsbad, CA,
USA), and 2 μg of RNA were reverse transcribed with M-
MLV Reverse Transcriptase (Promega, Madison, WI, USA)
according to the manufacturer’s protocol. The mRNA
expression level of TAZ was detected by the OneStep plus
7500 real-time PCR system (Bio-Rad, Hercules, CA, USA)
using SYBER Green PCR Master mix (Takara Bio, Inc.,
Shiga, Japan). The GAPDH expression level was used as an
endogenous control, and the mRNA level was calculated
using the 2−△△Ct method according to the manufacturer’s
instructions.
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shRNA lentivirus vector construction and cell infection
The TAZ-specific short hairpin RNA (shTAZ) and GFP-
specific short hairpin RNA (shGFP) were synthesized by
GenePharma Co., Ltd. (Shanghai, China) and subcloned
into the pLKO.1-puro lentivirus vectors. 293FT cells were
cotransfected with a lentivirus vector with shTAZ or shGFP,
and packaging plasmids using Lipofectamine 2000 (Life
Technologies). After 48 h of transfection, viral supernatants
were filtered and used to infect retinoblastoma cells. Stable
cells expressing TAZ and control shRNA were generated
after 5 days of culture with puromycin (4 μg/ml).
Flow cytometry
Retinoblastoma cells (1 × 106) were harvested and washed
twice with cold PBS. Then, they were fixed with 70 % cold
ethanol at 4 °C overnight. After two PBS washes, the cells
were incubated with propidiumiodide (PI; BD Biosciences)
and RNaseA for 30 min at room temperature. All samples
were analyzed by FACSCanto II (BD Biosciences) with
CellQuest software.
MTT Assay
To analyze cell proliferation, retinoblastoma cells were
seeded in 96-well plates at a density of 1000 cells per
well. Absorbance values were measured by a microplate
reader at 490 nm and the proliferation rates were ana-
lyzed by a cell growth curve. Each experiment was re-
peated independently at least three times.
Table 1 Patient demographics
Characteristic No. of patients n = 43,
n (%)
Patients 43 (100)
Age at presentation (y)
< 5 y 39 (90.7)










Unilateral (n = 34)
Right 21 (61.8)
Left 13 (38.2)























Largest tumor base (mm), mean (median, range) 11.3 (5–26)
≤ 15 mm 28 (58.1)
> 15 mm 15 (41.9)
Table 1 Patient demographics (Continued)
Tumor thickness (mm), mean (median, range) 8.6 (9, 3–16)
≤ 10 mm 25 (58.1)











Eye enucleated 19 (44.2)
Enucleated + chemotherapy 22 (51.2)






Zhang et al. Diagnostic Pathology  (2015) 10:187 Page 3 of 9
BrdU staining
Cells were grown on coverslips pre-coated with poly-L-
lysine (PLL), and then incubated with 10 μg/ml BrdU
(Sigma, St Louis, MO, USA) for 30 min. Next, the cells
were washed with PBS, fixed with 4 % paraformaldehyde
for 20 min, pre-treated with 1 mol/l HCl and blocked
with 10 % goat serum for 1 h. Coverslips were then incu-
bated with a monoclonal primary antibody against BrdU
(1:200; Abcam) overnight at 4 °C, and then with Alexa
FluorR® 594 goat anti-rat IgG secondary antibody for 2 h
(Invitrogen). Hoechst (1:1000) was used for counter-
staining. Images were captured from at least 10 micro-
scope fields (Nikon 80i, Nikon Corporation, Tokyo,
Japan) and analyzed using Image-Pro Plus software.
Statistical analysis
All experiments were performed at least in triplicate and
results were recorded. Statistical analysis was performed
with the Statistical Package for the Social Sciences Version
16.0 software (SPSS, Chicago, IL, USA). The TAZ mRNA
in retinoblastoma tissues and normal retina tissues was
analyzed using t-test analysis. The clinicopathological fea-
tures of retinoblastoma patients that correlated with TAZ
low and high expression groups were determined by the
Chi-square test. The TAZ expression in relation to overall
survival (OS), progression-free survival (PFS), loco-regional
relapse-free survival (LRRFS) and distant metastasis-free
survival (DMFS) rates was analyzed using the Kaplan-Meier
analysis and the log-rank test. The Cox regression analysis
Fig. 1 TAZ is commonly expressed in retinoblastoma a 1 and 2) Low immunohistochemical staining of TAZ in retinoblastoma. a 3 and 4) High
immunohistochemical staining of TAZ in retinoblastoma. b) mRNA level of TAZ in seven human retinoblastoma tissues and three normal retina
tissues were analyzed by quantitative real time-PCR
Fig. 2 Downregulation of TAZ inhibits retinoblastoma proliferation a) Western blot assay was used to analyze TAZ expression in TAZ-knockdown
Y79 cells. b) The effect of TAZ on the proliferation of Y79 cells was determined by the MTT assay. c) Western blot assay was used to analyze TAZ
expression in TAZknockdown WERI-Rb-1 cells. d) The effect of TAZ on the proliferation of WERI-Rb- 1 cells was determined by the MTT assay.
e–g) Images and quantification of Y79 and WERI-Rb-1 cells positive for BrdU staining. GAPDH was used as a loading control; student’s t-test was
carried out. All data are shown as mean ± SD, *P< 0.05, **P< 0.01
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was used for univariate analysis and multivariate analysis
of OS. P < 0.05 was considered statistically significant.
Results
Patient characteristics
Forty-three retinoblastoma patients were enrolled in this
study and their characteristics are summarized in Table 1.
At the time of diagnosis, the majority of the retinoblast-
oma patients were less than 5 years old and leukocoria
was the most common sign of retinoblastoma (79.1 %).
In the AJCC clinical classification (cTNM), there were
4.7 % in stage I, 27.9 % in stage II and 39.5 % in stage
III. In addition, 34.9 % of the retinoblastomas had a large
tumor base (>15 mm) and 44.2 % of the tumors were
poorly differentiated. Moreover, the growth pattern of
the retinoblastomas varied: 27.9, 46.5 and 11.6 % of the
patients had endophytic growth, exophytic growth and
mixed growth patterns, respectively.
Fig. 3 Downregulation of TAZ blocks the cell cycle transition from G1 to S phase a) The cell cycle of TAZ-knockdown Y79 cells was analyzed by
flow cytometry. b) The effects of TAZ on the cell cycle of Y79 cells. c) The cell cycle of TAZ-knockdown WERI-Rb-1cellswas analyzed flow
cytometry. d) The effects of TAZ on the cell cycle of WERI-Rb-1 cells. e and f) Western blot analysis of Cyclins and CDKs expression in TAZ-
knockdown Y79 and WERI-Rb-1 cells. g and h) Quantitative analysis of Cyclins and CDKs expression in TAZ-knockdown Y79 and WERI-Rb-1 cells;
GAPDH was used as a loading control; student’s t-test was carried out. All data are shown as mean ± SD, *P< 0.05, **P< 0.01
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TAZ expression in retinoblastoma and normal retina tissues
TAZ expression was investigated in retinoblastoma speci-
mens by immunohistochemistry (Fig. 1a). TAZ was highly
expressed in 65.1 % (28/43) of the retinoblastoma samples.
Next, RT-PCR was used to examine the TAZ mRNA level
in seven human retinoblastoma tissues (T0980, T2564,
T2837, T3049, T3746, T4824, T6385) and three human
normal retina tissues (N01, N04, N05). The five normal
retina tissues all showed TAZ mRNA expression. As
shown in Fig. 1b, TAZ mRNA had higher expression
in retinoblastoma tissues than in normal retina tissues
(P = 0.038). GAPDH mRNA expression of every tissue
was used as control for itself.
Downregulation of TAZ inhibits cell proliferation in
retinoblastoma cells
The effect of TAZ on retinoblastoma cell lines was de-
termined through lentivirus-mediated knockdown of
TAZ. Western blot analysis showed that the level of
TAZ expression significantly decreased in WERI-Rb-1
and Y79 retinoblastoma cells (Fig. 2a, c). Next, we ana-
lyzed the role of TAZ in the proliferation of retinoblast-
oma cells by the MTT assay. The results showed that
the proliferation of retinoblastoma cells was substantially
suppressed after TAZ knockdown (Fig. 2b, d). Further-
more, retinoblastoma cells with TAZ knockdown showed
a 39 % reductionin BrdU-positive cells compared with
the shGFP control group (Fig. 2e–g). These results sug-
gest that TAZ promotes proliferation in retinoblastoma
cell lines.
Downregulation of TAZ blocks cell cycle progression in
retinoblastoma cells
To further assess the effects of TAZ expression on ret-
inoblastoma, we used flow cytometry to analyze the cell
cycle of retinoblastoma cells (Fig. 3a–d). The results
showed that the number of cells in G1 phase in both
WERI-Rb-1 and Y79 cells increased after TAZ knock-
down. Moreover, we examined the expression levels of
Cyclins and Cyclin-dependent kinases (CDKs), which are
crucial for regulating the transition from G1 to S phase,
by western blot analysis. We found that the expression
of Cyclin E and CDK2 was downregulated in retinoblast-
oma cells with TAZ knockdown, but no obvious changes
were observed in Cyclin D1, CDK4 and CDK6 expres-
sion (Fig. 3e–h). These findings suggest that TAZ pro-
motes cell cycle progression via upregulation of Cyclin E
and CDK2.
Correlation between TAZ expression and clinicopathological
features
The correlation between clinicopathological features and
the expression level of TAZ is showed in Table 2. The
results showed that TAZ high expression significantly
correlated with regional lymph node classification (P =
0.013), largest tumor base (P = 0.045), and differentiation
(P = 0.019), but no significant correlation was observed be-
tween TAZ expression levels and the patients’ age, gender,
tumor enucleated location or tumor thickness.
Association of TAZ expression with OS, PFS, LRRFS and
DMFS
Until Dec 2014, there were 21 patients with progression, 18
patients with loco-regional relapse and 15 patients with dis-
tant metastasis, respectively. Kaplan-Meier analysis showed
that retinoblastoma patients with TAZ high expression had
shorter OS (P = 0.048), PFS (P = 0.012), LRRFS (P = 0.012)
and DMFS (P = 0.038) than those with TAZ low expression
(Fig. 4). The relationship between the 5-year OS, PFS,
Table 2 Correlation between clinicopathological features and




Expression of TAZ P value
High Low
Age at presentation (y) 28 15 0.602
< 5 y 39 (90.7) 26 13
≥ 5 y 4 (9.3) 2 2
Gender 28 15 0.338
Male 18 (41.9) 10 8
Female 25 (58.1) 18 7
Tumor enucleated location 28 15 1.000
Right 25 (58.1) 16 9
Left 18 (41.9) 12 6
cTNM classification
T classification 28 15 0.116
T1 + 2 24 13 11
T3 + 4 19 15 4
N classification 28 15 0.013*
N0 20 9 11
N1 + 2 23 19 4
cTNM stage 28 15 0.184
I + II 14 7 7
III + IV 29 21 8
Largest tumor base (mm) 28 15 0.045*
≤ 15 mm 28 (65.1) 15 13
> 15 mm 15 (34.9) 13 2
Tumor thickness (mm) 28 15 0.750
≤ 10 mm 25 (58.1) 17 8
> 10 mm 18 (41.9) 11 7
Differentiation 28 15 0.019*
Well and moderate 24 (55.8) 12 12
Poorly 19 (44.2) 16 3
*P < 0.05
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LRRFS and DMFS of retinoblastoma patients and the levels
of TAZ expression are shown in Table 3. Moreover, univari-
ate analysis demonstrated that primary tumor classification
(P = 0.002), regional lymph node classification (P = 0.012),
clinical stage (P = 0.026), largest tumor base (P = 0.040) and
differentiation (P = 0.002) were associated with a poor prog-
nosis (Table 4). Furthermore, the multivariate Cox regres-
sion analysis results revealed that advanced clinical stage
and TAZ high expression were associated with poor OS,
PFS, LRRFS and DMFS (Table 5).
Discussion
Accumulated research has revealed that TAZ plays a crit-
ical role in cell proliferation, survival and tissue growth
control [9, 17, 18]. Recently, high expression of TAZ has
been reported to be closely associated with carcinogenesis
in several human malignant cancers, such as oral squa-
mous cell carcinoma [19], breast cancer [20], lung cancer
[21], hepatocellular carcinoma [12] and ovarian cancer
[22]. However, whether TAZ is highly expressed in retino-
blastoma remains unclear. To obtain more insight into the
expression status and clinical significance of TAZ in ret-
inoblastoma, we performed immunohistochemistry stain-
ing to explore the expression level of TAZ and to analyze
its association with clinicopathological parameters of
retinoblastoma patients. Our results demonstrated that
TAZ was highly expressed in the majority of retinoblastoma
specimens and its expression correlated with regional lymph
node classification largest tumor base, and tumor differenti-
ation. More importantly, we also found that the TAZ ex-
pression was an important biomarker for prognosis of
patients with retinoblastoma. By knocking down TAZ ex-
pression with lentivirus-mediated shRNA interference, we
showed that downregulation of TAZ effectively decreased
retinoblastoma cell proliferation. Thus, our data suggest
that high TAZ levels promote retinoblastoma progression.
Fig. 4 Correlation between TAZ expression and OS, PFS, LRRFS and DMFS in retinoblastoma patients a) The Kaplan-Meier analysis of OS for
retinoblastoma patients with the log-rank test. b) The Kaplan-Meier analysis of PFS for retinoblastoma patients with the logrank test. c) The
Kaplan-Meier analysis of LRRFS for retinoblastoma patients with the log-rank test. d) The Kaplan-Meier analysis of DMFS for retinoblastoma
patients with the log-rank test. *P< 0.05
Table 3 Association of TAZ expression with 5-year survival in retinoblastoma patients
Group 5-year OS 5-year PFS 5-year LRRFS 5-year DMFS
Rate (%) P value Rate (%) P value Rate (%) P value Rate (%) P value
TAZ
High expression 60.7 0.048* 42.9 0.012* 50.0 0.024* 57.1 0.038*
Low expression 80.0 66.7 73.3 80.0
*P < 0.05
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Retinoblastoma is the most common eye cancer in
children, which is caused by mutation of the RB1 gene
[23–25]. It occurs in approximately 1 per 15,000–20,000
live births and there are about 9000 new cases every year
[26]. Retinoblastoma was the first tumor to emphasize
the genetic aberrations in carcinogenesis. Despite good
understanding of its etiology, about 40–70 % of children
suffering from retinoblastoma die in developing coun-
tries in Africa and Asia [24]. Therefore, it is necessary to
further dissect the underlying mechanisms of retino-
blastoma initiation and development, to find valuable
therapeutic targets.
In this study, we found that TAZ expression was associ-
ated with regional lymph node classification, largest tumor
base, and tumor differentiation, suggesting that TAZ is
involved in retinoblastoma development. More import-
antly, we demonstrated that high TAZ expression was sig-
nificantly associated with shorter OS, PFS, LRRFS and
DMFS time in patients with retinoblastoma. The results
form Kaplan-Meier analysis and the log-rank test showed
that patients whose tumors had higher TAZ expression
tended to have a significantly worse overall survival rate,
indicating that a high TAZ level is a biomarker of poor
prognosis for patients with retinoblastoma. In addition,
the Cox proportional hazards regression model showed
that high TAZ expression was a biomarker of worse OS.
Furthermore, our data showed that knockdown of TAZ
expression in retinoblastoma cells blocked the cell cycle
transition from G1 to S phase and decreased the protein
expression of Cyclin E and CDK2, again suggesting that
TAZ participates in the regulation of cell cycle pathways
in retinoblastoma cells. In summary, we demonstrated
that TAZ promotes retinoblastoma growth via downregu-
lating Cyclin E and CDK2 expression. Therefore, our data
showed that TAZ expression represents a potential bio-
marker for predicting the prognosis of patients with ret-
inoblastoma and for identifying patients in higher risk of
death.
Table 4 Cox univariate analysis of overall survival
Variables SE value Hazard ratio Risk ratio (95 % CI) P value
Age (≥5 y) 1.043 0.835 0.108–6.451 0.863
Gender (female) 0.558 0.806 0.270–2.409 0.700
Tumor enucleated location (left) 0.536 0.702 0.246–2.006 0.702
Primary tumor (cT3 + T4) 0.680 0.122 0.032–0.462 0.002*
Regional lymph node (cN1 + N2) 0.793 0.135 0.028–0.638 0.012*
cTNM stage (III + IV) 1.043 0.098 0.013–0.760 0.026*
Largest tumor base (>15 mm) 0.591 0.297 0.093–0.948 0.040*
Tumor thickness (>10 mm) 0.545 0.668 0.230–1.943 0.459
Differentiation (poorly) 0.789 0.085 0.018–0.401 0.002*
TAZ high expression 0.601 0.314 0.112–1.129 0.042*
*P < 0.05
Table 5 Cox multivariate analysis for retinoblastoma patients
Variables SE value Hazard ratio Risk ratio (95 % CI) P Value
OS
cTNM stage (III + IV) 1.065 0.085 0.011–0.687 0.021*
TAZ high expression 0.756 0.226 0.051–0.994 0.049*
PFS
cTNM stage (III + IV) 1.097 0.030 0.003–0.254 0.001*
TAZ high expression 0.692 0.144 0.037–0.559 0.005*
LRRFS
cTNM stage (III + IV) 1.062 0.056 0.007–0.452 0.007*
TAZ high expression 0.710 0.195 0.049–0.783 0.021*
DMFS
cTNM stage (III + IV) 1.058 0.084 0.011–0.672 0.019*
+TAZ high expression 0.735 0.228 0.054–0.960 0.044*
*P < 0.05
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Conclusions
In summary, our results proved that high expression of
TAZ promoted proliferation of retinoblastoma cells and
was associated with poor prognosis for patients with ret-
inoblastoma, suggesting that TAZ may serve as a valuable
biomarker for predicting the clinical prognosis of patients
with retinoblastoma and is a potential therapeutic target.
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